NO152903B - PROCEDURE FOR PREPARING IMIDAZOLE COMPOUNDS - Google Patents

PROCEDURE FOR PREPARING IMIDAZOLE COMPOUNDS Download PDF

Info

Publication number
NO152903B
NO152903B NO771453A NO771453A NO152903B NO 152903 B NO152903 B NO 152903B NO 771453 A NO771453 A NO 771453A NO 771453 A NO771453 A NO 771453A NO 152903 B NO152903 B NO 152903B
Authority
NO
Norway
Prior art keywords
methyl
mol
added
mixture
formula
Prior art date
Application number
NO771453A
Other languages
Norwegian (no)
Other versions
NO152903C (en
NO771453L (en
Inventor
Joseph James Lewis
Robert Lee Webb
Original Assignee
Smithkline Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/771,044 external-priority patent/US4119781A/en
Application filed by Smithkline Corp filed Critical Smithkline Corp
Publication of NO771453L publication Critical patent/NO771453L/en
Publication of NO152903B publication Critical patent/NO152903B/en
Publication of NO152903C publication Critical patent/NO152903C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

Foreliggende oppfinnelse vedrører en fremgangsmåte for fremstilling av substituerte imidazolforbindelser som er nyttige som utgangsmateriale ved fremstilling av visse histamin tt^-antagonister. Spesielt vedrører oppfinnelsen en frem- The present invention relates to a method for the production of substituted imidazole compounds which are useful as starting material in the production of certain histamine tt^-antagonists. In particular, the invention relates to a

gangsmåte for fremstilling av 4-(oksy, tio eller amino)-metylimi-dazoler via fortrengning av den trisubstituerte fosfoniumgruppe fra en 4-(trisubstituert fosfonium)-metylimidazolforbindelse som illustreres som følger procedure for the preparation of 4-(oxy, thio or amino)-methylimidazoles via displacement of the trisubstituted phosphonium group from a 4-(trisubstituted phosphonium)-methylimidazole compound which is illustrated as follows

hvor R<1> er hydrogen eller alkyl med 1-4 C-atomerfortrinnsvis metyl, R 2 er metoksy, etoksy, n-propoksy, n-butoksy, i-butoksy, t-butoksy, eller -NR<6>R<7 >hvor R<6> og R<7> hver er hydrogen, alkyl med 1-4 C-atomer eller sammen med nitrogenatomet hvortil de er bundet danner en piperidin, pyrrolidin eller morfolinring, R3 er hydrogen, alkyl med 1-4 C-atomer eller trifluormetyl, eller -SR<4>, hvor 4 c R er alkyl med 1-4 C-atomer, benzyl eller klorbenzyl, R er alkyl med 1-4 C-atomer eller fortrinnsvis fenyl, og X er halogen, fortrinnsvis klor eller brom. Fortrinnsvis er R<2>where R<1> is hydrogen or alkyl with 1-4 C atoms, preferably methyl, R 2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy, or -NR<6>R<7 >where R<6> and R<7> are each hydrogen, alkyl with 1-4 C atoms or together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine or morpholine ring, R3 is hydrogen, alkyl with 1-4 C- atoms or trifluoromethyl, or -SR<4>, where 4 c R is alkyl of 1-4 C atoms, benzyl or chlorobenzyl, R is alkyl of 1-4 C atoms or preferably phenyl, and X is halogen, preferably chlorine or bromine. Preferably, R<2>

Forbindelsene med formel II, som fremstilles i henhold til The compounds of formula II, which are prepared according to

den nye fremgangsmåte, er blant annet beskrevet i US patentene nr. 3.950.333 og 3.950'. 353. Forbindelsene med formel II er nyttige som utgangsmaterialer for fremstilling av farmakologisk aktive forbindelser is'ær histamin H9-antagonister, f.eks. N-cyano-N1-metyl-N"-[2-(5-R 1-imidazolyl-metyltio)etyl]-guanidin og N-metyl-N1 -[2-(5-R -imidazolylmetyltio)-etyl]tioureaforbindelser. Ifølge ovenstående fremgangsmåte bevirkes fortrengningen av en trisubstituert fosfoniumgruppe [-P(R ).,] i en forbindelse av formel I ved reaksjon av en forbindelse av formel I med R 2H under basiske betingelser, dvs. med R 2H i form av dens anion the new method is described, among other things, in US patents no. 3,950,333 and 3,950'. 353. The compounds of formula II are useful as starting materials for the preparation of pharmacologically active compounds, especially histamine H9 antagonists, e.g. N-cyano-N1-methyl-N"-[2-(5-R 1-imidazolyl-methylthio)ethyl]-guanidine and N-methyl-N1-[2-(5-R-imidazolylmethylthio)-ethyl]thiourea compounds. According to the above method, the displacement of a trisubstituted phosphonium group [-P(R ).,] in a compound of formula I is effected by reaction of a compound of formula I with R 2H under basic conditions, i.e. with R 2H in the form of its anion

2 0 2 0

R . Anionet kan dannes ved reaksjon in situ av en forbin-deise av formel R <2>H og en sterk base. Blant de baser som kan anvendes ved fremgangsmåten ifølge oppfinnelsen er de som er i stand til å fjerne protonet fra en forbindelse av formel R . The anion can be formed by reaction in situ of a compound of the formula R<2>H and a strong base. Among the bases which can be used in the method according to the invention are those which are capable of removing the proton from a compound of the formula

2 2 0 2 2 2 0 2

R H til dannelse av anionet R , hvor R er som ovenfor definert. Slike baser er de som har en pKa større enn 12, f.eks. alkalimetallalkoksydene såsom natriummetoksyd eller etoksyd eller metallhydridene såsom natriumhydrid som foretrekkes. Når R 2 H selv er tilstrekkelig basisk f.eks. når R 2H er piperidin, R H to form the anion R , where R is as defined above. Such bases are those with a pKa greater than 12, e.g. the alkali metal alkoxides such as sodium methoxide or ethoxide or the metal hydrides such as sodium hydride which are preferred. When R 2 H itself is sufficiently basic, e.g. when R 2H is piperidine,

er det ikke nødvendig å tilsette noen ytterligere base. I de it is not necessary to add any additional base. In those

2 2 6 7 tilfeller hvor R H er ytterst flyktig såsom når R er -NR R 6 7 2 2 6 7 cases where R H is extremely volatile such as when R is -NR R 6 7

og.den ene eller begge av R og R er hydrogen foretrekkes det at R 2H er i form av et metalat, f.eks. natrium eller litium-metalat, såsom natriumamid. Fortrinnsvis er det tilstede et and one or both of R and R is hydrogen, it is preferred that R 2H is in the form of a metalate, e.g. sodium or lithium metalate, such as sodium amide. Preferably there is a

2 2

lite overskudd av R H. little surplus of R H.

Reaksjonen utføres i et organisk oppløsningsmiddel og oppløs-ningsmidler såsom metanol, etanol, propanol, butanol, aceton, acetonitril, dimetylformamid og dimetylsulfoksyd foretrekkes. Fortrinnsvis utføres reaksjonen ved en temperatur fra omgivelsestemperatur til tilbakekjølingstemperaturen for det til reaksjonen anvendte oppløsningsmiddel, nemlig fra 25°C The reaction is carried out in an organic solvent and solvents such as methanol, ethanol, propanol, butanol, acetone, acetonitrile, dimethylformamide and dimethylsulfoxide are preferred. Preferably, the reaction is carried out at a temperature from ambient temperature to the cooling temperature of the solvent used for the reaction, namely from 25°C

til 200°C, idet 65°C til 100°C er mest hensiktsmessig i 20 min. til 24 timer, fortrinnsvis fra 20 min. til to 200°C, with 65°C to 100°C being most suitable for 20 min. to 24 hours, preferably from 20 min. to

3 timer 3 hours

i in

Fortrinnsvis opparbeides reaksjonsblandingen ved fortynning med vann og fjernelse av trialkyl- eller trifenylfosfinbiproduktet ved filtrering- Ekstraksjon av filtratet, når dette er nødven-dig, etterfulgt av inndampning, gir forbindelsene av formel II. Det er ofte ønskelig å omdanne forbindelsene av formel II til Preferably, the reaction mixture is worked up by dilution with water and removal of the trialkyl or triphenylphosphine by-product by filtration. Extraction of the filtrate, when necessary, followed by evaporation, gives the compounds of formula II. It is often desirable to convert the compounds of formula II into

de tilsvarende salter, fortrinnsvis hydrokloridene. Disse salter fremstilles ved å behandle en oppløsning av imdazolet av formel II med en syre eller sur oppløsning, f.eks. med en eterisk eller etanolisk oppløsning av saltsyre og krystallisere det dannede salt av et passende oppløsningsmiddel. the corresponding salts, preferably the hydrochlorides. These salts are prepared by treating a solution of the imidazole of formula II with an acid or acidic solution, e.g. with an ethereal or ethanolic solution of hydrochloric acid and crystallizing the formed salt from a suitable solvent.

De 4-(trisubstituert fosfonium)-metylimidazoler av formel I fremstilles ved reaksjon av et trisubstituert $-acylvinylfos-foniumhalogenid, fortrinnsvis bromid eller klorid med formelen The 4-(trisubstituted phosphonium)-methylimidazoles of formula I are prepared by reaction of a trisubstituted 4-acylvinylphosphonium halide, preferably bromide or chloride, with the formula

hvor R 1 , R 5 og X er som ovenfor definert med en forbindelse av formelen where R 1 , R 5 and X are as above defined with a compound of the formula

hvor R 3 er som ovenfor definert bortsett fra hydrogen ved fremgangsmåten som er beskrevet av Zbiral, Synthesis 11:775 (1974) og Zbiral og Hugl, Phosphorus 2:29 (1972). Når R<3> er hydrogen fremstilles de tilsvarnede 4-(trisubstituert fosfonium)metyl-imidazoler av formelen I også ved reaksjon av trikloracetamidin eller formamidinsulfinsyre med et trifenyl (J-acylvinylfos-foniumhalogenid. Ved formamidinsulfinsyreprosessen anvendes en base, fortrinnsvis en ikke nukleofil base, såsom et tertiært amin. where R 3 is as defined above except for hydrogen by the method described by Zbiral, Synthesis 11:775 (1974) and Zbiral and Hugl, Phosphorus 2:29 (1972). When R<3> is hydrogen, the corresponding 4-(trisubstituted phosphonium)methyl-imidazoles of the formula I are also prepared by reaction of trichloroacetamide or formamidinesulfinic acid with a triphenyl (J-acylvinylphosphonium halide. In the formamidinesulfinic acid process, a base is used, preferably a non-nucleophilic base , such as a tertiary amine.

For å fremstille de trisubstituerte 3-acylvinylfosfoniumhalo-genider som hittil ikke er kjent behandles et halogenvinylalkyl-keton såsom klorvinylmetylketon med et trilakyl- eller trifenylfosfin. Når R er hydrogen fremstilles de trisubstituerte &-formylvinylfosfoniumhalogenider ved oksydasjon av en 3-halo-genallylalkohol såsom p-klorallylalkohol og behandling av det således dannede produkt med et trialkyl- eller "trifenylfosfin. To prepare the hitherto unknown trisubstituted 3-acylvinylphosphonium halides, a halovinylalkylketone such as chlorovinylmethylketone is treated with a trialkyl or triphenylphosphine. When R is hydrogen, the trisubstituted &-formylvinylphosphonium halides are prepared by oxidizing a 3-halogenallyl alcohol such as p-chloroallyl alcohol and treating the product thus formed with a trialkyl or "triphenylphosphine.

Imidazolforbindelsene av formel II fremstilt ved fremgangsmåten ifølge oppfinnelsen er nyttige som utgangsraaterialer til fremstilling av farmakologisk aktive forbindelser især histamin H_-antagonister, f.eks. N-cyano-N1-metyl-N"-[2-(5-R 1-imidazolyl-metyltio)etyl]-guanidin og N-metyl-N'- 12-(5-R^-imidazolylmetyl-tio)-etyl]tioureafqrbindelser. Histamin ^-antagonister virker ved histamin t^-reseptorer som er beskrevet av Black med flere [Nature 236:385 (1972)] som kan defineres som de hista-minreseptorer som ikke blokkeres av "antihistaminer" såsom mepyramin, men blokkeres av burimamid. Blokkering av histamin I^-reseptorer har anvendelighet til hindring av biologiske vir-kninger av histamin som ikke hindres av "antihistaminer". Histamin ^-antagonister er nyttige, f.eks. som inhibitorer av mavesyresekresjon. The imidazole compounds of formula II produced by the method according to the invention are useful as starting materials for the production of pharmacologically active compounds, especially histamine H-antagonists, e.g. N-cyano-N1-methyl-N"-[2-(5-R 1-imidazolyl-methylthio)ethyl]-guanidine and N-methyl-N'- 12-(5-R^-imidazolylmethyl-thio)-ethyl ]thioureafqr compounds Histamine t-antagonists act at histamine t-receptors described by Black with several [Nature 236:385 (1972)] which can be defined as those histamine receptors which are not blocked by "antihistamines" such as mepyramine, but are blocked of burimamide. Blockade of histamine I^ receptors has utility in blocking biological effects of histamine that are not prevented by "antihistamines." Histamine ^ antagonists are useful, eg, as inhibitors of gastric acid secretion.

Omdannelse av forbindelsene av formel II til de farmakologisk aktive guanidin og tioureaprodukter kan .utføres på -forskjel-2 3 Conversion of the compounds of formula II to the pharmacologically active guanidine and thiourea products can be carried out in -difference-2 3

lige mater. Nar R er -SCH2CH2NH2 og R er hydrogen, lavere alkyl, trifluormetyl, benzyl eller amino, behandles 4-(2-aminoetyl)tiometylamidazolforbindelsen av formel II med metylisotiocyanat til dannelse av de tilsvarende N-metyl-N[2-(5-R^-imidazolylmetyltio)etyl]-tiourea. Reaksjon av straight feed. When R is -SCH2CH2NH2 and R is hydrogen, lower alkyl, trifluoromethyl, benzyl or amino, the 4-(2-aminoethyl)thiomethylamidazole compound of formula II is treated with methyl isothiocyanate to form the corresponding N-methyl-N[2-(5-R ^-imidazolylmethylthio)ethyl]-thiourea. Reaction of

samme 4-(2-aminoetyl)tiometylimidazolforbindelse med N-cyano-N',S-dimetylisotiourea gir de tilsvarende N-cyano-N'-metyl-N"-[2-(5-R^-imidazolylmetyltio)etyl]-guanidiner. same 4-(2-aminoethyl)thiomethylimidazole compound with N-cyano-N',S-dimethylisothiourea gives the corresponding N-cyano-N'-methyl-N"-[2-(5-R^-imidazolylmethylthio)ethyl]-guanidines .

1 1

Guanidinproduktene fremstilles også ved reaksjon av 4-(2-amino-etyl )-tiometylimidazol med dimetyl-N-cyanoimidoditiokarbonat og påfølgende reaksjon av det fremkomne N-cyano-N'-[2-(5-R<1->imida-zolylmetyltio)etyl]-S-metylisotiourea med metylamin. Når <2> er The guanidine products are also produced by reaction of 4-(2-amino-ethyl)-thiomethylimidazole with dimethyl-N-cyanoimidodithiocarbonate and subsequent reaction of the resulting N-cyano-N'-[2-(5-R<1->imidazolylmethylthio) )ethyl]-S-methylisothiourea with methylamine. When <2> is

R er R is

fremstilles guanidinproduktene direkte ved fremgangsmåten ifølge oppfinnelsen. the guanidine products are produced directly by the method according to the invention.

2 3 4 4 2 3 4 4

Når R er -SCH2CH2NH2 og R er -SR , hvor R er som ovenfor definert behandles forbindelsene av formel II med et reduksjonsmiddel f.eks. med Raney-nikkel til dannelse av de tilsvarende 4-(2-aminoetyl)tiometylimidazoler, hvor R 3er hydrogen, som deretter omdannes til guanidin og tioureaproduktene som oven- When R is -SCH2CH2NH2 and R is -SR, where R is as defined above, the compounds of formula II are treated with a reducing agent, e.g. with Raney nickel to form the corresponding 4-(2-aminoethyl)thiomethylimidazoles, where R 3 is hydrogen, which are then converted to guanidine and the thiourea products as above

for beskrevet. Når R 2er too described. When R 2 is

og R 3 er -SR 4 gir behandling med et reduksjonsmiddel guanidin-produktet direkte. and R 3 is -SR 4 treatment with a reducing agent gives the guanidine product directly.

Nar R 2er metoksy, etoksy, n-propoksy, n-butoksy, i-butoksy, When R 2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy,

6 7 3 4 4 6 7 3 4 4

t-butoksy eller -NR R , og R er -SR , hvor R er som ovenfor definert fjernes -SR 4-gruppen i forbindelsene av formel II t-butoxy or -NR R , and R is -SR , where R is as defined above, the -SR 4 group is removed in the compounds of formula II

som ovenfor beskrevet,og de således dannede produkter behandles så med cysteamin til dannelse av 4-(2-aminoetyl)tiometylimida-zolforbindelsene hvor R 3 er hydrogen som omdannes til guanidin og tioureaproduktene som tidligere beskrevet. as described above, and the thus formed products are then treated with cysteamine to form the 4-(2-aminoethyl)thiomethylimidazole compounds where R 3 is hydrogen which is converted to guanidine and the thiourea products as previously described.

Nåo r R 2 er metoksy, etoksy, n-propoksy, n-butoksy, i-butoksy, When R 2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy,

6 7 '3 6 7 '3

t-butoksy eller -NR R og R er hydrogen behandles forbindelsene av formel II med cysteamin til dannelse av 4-(2-amino-etyl ) tiometylimidazolene som derpå omdannes til guanidin og tioureaproduktene som tidligere beskrevet. t-butoxy or -NR R and R is hydrogen, the compounds of formula II are treated with cysteamine to form the 4-(2-amino-ethyl) thiomethylimidazoles which are then converted to guanidine and the thiourea products as previously described.

Disse tiour.ea og cyanoguanidinproduktene fremstilt av forbindelsene av formel II er beskrevet i de amerikanske paten-ter nr. 3.950.333 og 3.950.353. These thiourea and cyanoguanidine products prepared from the compounds of formula II are described in US Patent Nos. 3,950,333 and 3,950,353.

De følgende eksempler illustrerer oppfinnelsen. Temperaturene er i °c, med mindre annet er anført. The following examples illustrate the invention. Temperatures are in °c, unless otherwise stated.

Eksempel 1 Example 1

Metallisk natrium (25,3 g, 1,1 mol) ble oppløst i 2 liter etanol. 2-metylpseudotioureasulfat : (278,3 g, 1,0 mol) ble tilsatt, Sodium metal (25.3 g, 1.1 mol) was dissolved in 2 liters of ethanol. 2-Methylpseudothiourea sulfate: (278.3 g, 1.0 mol) was added,

og blandingen ble omrørt i 1/2 time. Deretter ble 411 g (1,0 mol) trifenyl-|3-acetylvinylfosfoniumbromid tilsatt og blandingen ble oppvarmet under tilbakekjøling i 18 timer, avkjølt og filtrert. Filterkaken ble vasket med 200 ml etanol. Filtrat og etanolvaskevæskene ble forenet og inndampet under redusert trykk og etterlot en brun rest. 500 ml kloroform ble tilsatt resten og blandingen ble omrørt i noen få minutter og deretter filtrert. Filterkaken ble vasket 3 ganger med porsjoner på 150 ml kloroform og tørket til dannelse av 364 g (75%) [(2-metyltio-5-metylimida-zolyl)-4-metylJtrifenylfosfoniumbromid. Smp. 223-225°C. and the mixture was stirred for 1/2 hour. Then 411 g (1.0 mol) of triphenyl-|3-acetylvinylphosphonium bromide was added and the mixture was heated under reflux for 18 hours, cooled and filtered. The filter cake was washed with 200 ml of ethanol. The filtrate and ethanol washings were combined and evaporated under reduced pressure leaving a brown residue. 500 ml of chloroform was added to the residue and the mixture was stirred for a few minutes and then filtered. The filter cake was washed 3 times with 150 ml portions of chloroform and dried to give 364 g (75%) of [(2-methylthio-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide. Temp. 223-225°C.

Cysteamin (12,23 g, 0,13 mol) ble oppløst i 100 ml metanol og Cysteamine (12.23 g, 0.13 mol) was dissolved in 100 mL of methanol and

det ble tilsatt 46,5 ml 25% vekt/volum natriummetoksydoppløs-ning. Etter omrøring ved omgivelsestemperatur i 10 min. 46.5 ml of 25% weight/volume sodium methoxide solution was added. After stirring at ambient temperature for 10 min.

ble det faste fosfoniumsalt tilsatt og blandingen ble oppvarmet under tilbakekjøling i 20 min.. Oppløsningen ble fortynnet med 2 ganger sitt volum isvann og omrørt. Det utfelte trifenylfosfin ble fjernet ved filtrering. Filtratet ble ekstrahert med 3 porsjoner på 100 ml kloroform og kloroformekstraktene ble tørket og inndampet til tørrhet og ga 19 g (86%) 4-(2-aminoetyl)-tiometyl-5-metyl-2-metyltioimidazol som en viskøs olje. the solid phosphonium salt was added and the mixture was heated under reflux for 20 min. The solution was diluted with 2 times its volume of ice water and stirred. The precipitated triphenylphosphine was removed by filtration. The filtrate was extracted with 3 portions of 100 ml chloroform and the chloroform extracts were dried and evaporated to dryness to give 19 g (86%) of 4-(2-aminoethyl)-thiomethyl-5-methyl-2-methylthioimidazole as a viscous oil.

Behandling av 4-(2-aminoetyl)tiometyl-5-metyl-2-metyltioimida- Treatment of 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimida-

zol med etanolisk saltsyre ga det tilsvarende dihydrokloridsalt, smeltepunkt 165;°C (etanol-etylacetat) . sol with ethanolic hydrochloric acid gave the corresponding dihydrochloride salt, melting point 165 °C (ethanol-ethyl acetate).

Eksempel 2 Example 2

En oppløsning av 48,3 g (0,1 mol) [(5-metyl-2-metyltioimidazolyl)-4-metyl]trifenylfosfoniumbromid i 250 ml metanol ble tilsatt hurtig ved omgivelsestemperatur til en omrørt oppløsning av A solution of 48.3 g (0.1 mol) [(5-methyl-2-methylthioimidazolyl)-4-methyl]triphenylphosphonium bromide in 250 ml of methanol was added rapidly at ambient temperature to a stirred solution of

i in

35 ml 25% natriummetdksyd i metanol i 250 ml metanol. Blandingen ble oppvarmet under tilbakekjøling i 20 min. og deretter konsentrert til sitt halve volum. Etter fortynning med 900 ml-vann ble trifenylfosfinet fjernet ved filtrering. Den vandige oppløsning ble ekstrahert 2 ganger med porsjoner på 150 ml benzen og deretter 3 ganger med porsjoner på 250 ml kloroform. Klorof ormekstraktene ble tørket (MgSO^) og inndampet til tørrhet og ga 13 g (76 %) 4-metoksymetyl-5-metyl-2-metyltioimidazol. Smeltepunktet til pikratsaltet av 4-metoksymetyl-5-metyl-2-metyltioimidazol er 110-lll°c. 35 ml of 25% sodium methoxide in methanol in 250 ml of methanol. The mixture was heated under reflux for 20 min. and then concentrated to half its volume. After dilution with 900 ml of water, the triphenylphosphine was removed by filtration. The aqueous solution was extracted 2 times with 150 ml portions of benzene and then 3 times with 250 ml portions of chloroform. The chloroform extracts were dried (MgSO 4 ) and evaporated to dryness to give 13 g (76%) of 4-methoxymethyl-5-methyl-2-methylthioimidazole. The melting point of the picrate salt of 4-methoxymethyl-5-methyl-2-methylthioimidazole is 110-11°C.

Eksempel 3 Example 3

Metallisk natrium (2,3 g, 0,1 mol) ble oppløst i etanol, og under omrøring ble det tilsatt 9,5 g (0,1 mol) acetamidinhydroklorid. Etter 10 min. ble det tilsatt 41,1 g (0,1 mol) trifenyl-p-acetylvinylfosfoniumbromid og blandingen ble oppvarmet under tilbake-kjøling i 17 timer. Blandingen ble filtrert og filtratet inndampet til tørrhet til dannelse av et brunlig fast stoff som ble henstilt med 300 ml kloroform. 100 ml etylacetat ble tilsatt og bunnfallet ble oppsamlet ved filtrering og vasket med 100 ml aceton til dannelse av 36 g (80%) [(2,5-dimetylimidazolyl)-4-metyl]trifenylfosfoniumbromid. Smp. 239-240°C. Sodium metal (2.3 g, 0.1 mol) was dissolved in ethanol and, with stirring, 9.5 g (0.1 mol) of acetamidine hydrochloride was added. After 10 min. 41.1 g (0.1 mol) of triphenyl-p-acetylvinylphosphonium bromide was added and the mixture was heated under reflux for 17 hours. The mixture was filtered and the filtrate evaporated to dryness to give a brownish solid which was quenched with 300 ml of chloroform. 100 ml of ethyl acetate was added and the precipitate was collected by filtration and washed with 100 ml of acetone to give 36 g (80%) of [(2,5-dimethylimidazolyl)-4-methyl]triphenylphosphonium bromide. Temp. 239-240°C.

Når en ekvivalent mengde [(2,5-dimetylimidazolyl)-4-metyl]tri-fenylfosfoniumbromid anvendes i fremgangsmåtene i eksempel 1 og 2 i stedet for [ (2-metyltio-5-metylimidazolyl).-4-metyl] trifenyl-fosfoniumbromid fås henholdsvis 4-(2-aminoetyl)tiometyl-2,5-dimetylimidazol og 2,5-dimetyl-4-metoksymetylimidazol. When an equivalent amount of [(2,5-dimethylimidazolyl)-4-methyl]triphenylphosphonium bromide is used in the methods of Examples 1 and 2 instead of [(2-methylthio-5-methylimidazolyl).-4-methyl]triphenylphosphonium bromide 4-(2-aminoethyl)thiomethyl-2,5-dimethylimidazole and 2,5-dimethyl-4-methoxymethylimidazole are obtained, respectively.

Eksempel 4 Example 4

(a) Trikloracetamidin (1,62 g, 0,1 mol) ble oppløst i 20 ml tørt dimetylsulfoksyd, og det ble tilsatt 4,1 g (0,1 mol) trifenyl-3-acetylvinylfosfoniumbromid i 40 ml dimetylsulfoksyd i en porsjon under omrøring. Den eksoterme reaksjonsblanding ble gradvis lysere i farve og ble oppvarmet til 100°C i 10 min.. Avdampning av oppløsningsmidlet ga [(5-metylimidazolyl)-4-metyl]trifenyl-fosfoniumbromid. (a) Trichloroacetamide (1.62 g, 0.1 mol) was dissolved in 20 mL of dry dimethyl sulfoxide, and 4.1 g (0.1 mol) of triphenyl-3-acetylvinylphosphonium bromide in 40 mL of dimethyl sulfoxide was added in one portion under stirring. The exothermic reaction mixture gradually became lighter in color and was heated to 100°C for 10 min. Evaporation of the solvent gave [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.

Alternativt og fortrinnsvis fremstilles fosfoniumbromidet ved Alternatively and preferably, the phosphonium bromide is prepared by

å anvende trikloracetamidin ved følgende fremgangsmåte: Trifenyl-p-acetylvinylfosfoniumbromid (8,0 g, 0,019 mol) ble oppløst i en minimal mengde tørt acetonitril (ca. 100 ml), og 4,0 g (0,25 mol) trikloracetamidin ble tilsatt i en porsjon. to use trichloroacetamide by the following procedure: Triphenyl-p-acetylvinylphosphonium bromide (8.0 g, 0.019 mol) was dissolved in a minimal amount of dry acetonitrile (about 100 ml), and 4.0 g (0.25 mol) of trichloroacetamide was added in one portion.

Den fremkomne blanding ble omrørt ved romtemperatur og materialet som utkrystalliserte ble frafiltrert til dannelse av [(2-tri-klormetyl-5-metylimidazolyl)-4-metyl]trifenylfosfoniumbromid. The resulting mixture was stirred at room temperature and the material that crystallized was filtered off to form [(2-tri-chloromethyl-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.

Smp. 155-157°c. Temp. 155-157°c.

Dette fosfoniumsalt (15,0 g, 0,027 mol) ble satt til 150 ml metanol og den fremkomne blanding ble oppvarmet under tilbakekjøling i 3 timer. Blandingen ble konsentrert til ca. 15 ml og det faste materialet ble frafiltrert til dannelse av [(2-metoksy-. karbonyl-5-metylimidazolyl)-4-metyl]trifenylfosfoniumbromid. Smp. 168-170°C, utbytte 89 %. This phosphonium salt (15.0 g, 0.027 mol) was added to 150 mL of methanol and the resulting mixture was heated under reflux for 3 hours. The mixture was concentrated to approx. 15 ml and the solid material was filtered off to form [(2-methoxy-.carbonyl-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide. Temp. 168-170°C, yield 89%.

Det ovenfor fremstilte fosfoniumsalt oppvarmes til sitt smeltepunkt (ca. 170°C) og ble holdt ved denne temperatur inntil gass-utviklingen er avsluttet. Etter avkjøling tritureres det faste produkt med kloroform til dannelse av [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumbromid. Smp. 238-239°C, utbytte 70 %. The phosphonium salt prepared above is heated to its melting point (approx. 170°C) and kept at this temperature until gas evolution has ended. After cooling, the solid product is triturated with chloroform to form [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide. Temp. 238-239°C, yield 70%.

Trifenyl-&-acetylvinylfosfoniumklorid (36 g, 0,01 mol) og trikloracetamidin (16,1 g, 0,1 mol) ble omrørt i 200 ml metanol i 1 time. Oppløsningen ble oppvarmet under tilbakekjøling, avkjølt og metanolet avdampet til dannelse av [(2-metoksykarbonyl-5-metylimidazolyl)-4-metyl]trifenylfosfoniumklorid. Oppvarmning av dette fosfoniumklorid til 17 0°C inntil utviklingen av gass er avsluttet og deretter avkjøling og triturering med kloroform gir [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumklorid. Smp. 225-227°C, utbytte 65 %. (b) Formamidinsulfihsyre (11,0 g, 0,1 mol) ble suspendert i 250 ml tørt dimetylsulfoksyd og det ble tilsatt 2,4 g (0,1 mol) natriumhydrid. Etter avslutning av hydrogenutviklirig ble det tilsatt.36,5 g (0,1 mol) trif enyl-[3-acetylvinylf osf oniumklorid og blandingen ble omrørt i 1 time ved omgivelsestemperatur og deretter oppvarmet til 100°C i 10 min.. Etter avkjøling ble di-metylsulf oksydet avdampet og resten ble oppløst i 300 ml 1:1 kloroformmetanol, og oppløsningen filtrert. Filtratet ble inndampet til tørrhet og resten ble omkrystallisert av kloroform-aceton til dannelse av 20 g (50%) [(5-metylimidazolyl)-4-metyl}-trifenylfosfoniumklorid, smeltepunkt 223 - 225°C. Triphenyl-α-acetylvinylphosphonium chloride (36 g, 0.01 mol) and trichloroacetamide (16.1 g, 0.1 mol) were stirred in 200 mL of methanol for 1 hour. The solution was heated under reflux, cooled and the methanol evaporated to give [(2-methoxycarbonyl-5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride. Heating this phosphonium chloride to 170°C until evolution of gas has ceased and then cooling and trituration with chloroform gives [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride. Temp. 225-227°C, yield 65%. (b) Formamidinesulfuric acid (11.0 g, 0.1 mol) was suspended in 250 ml of dry dimethyl sulfoxide and 2.4 g (0.1 mol) of sodium hydride was added. After completion of hydrogen evolution, 36.5 g (0.1 mol) of triphenyl-[3-acetylvinylphosphonium chloride was added and the mixture was stirred for 1 hour at ambient temperature and then heated to 100°C for 10 min. After cooling the dimethyl sulphoxide was evaporated and the residue was dissolved in 300 ml of 1:1 chloroform methanol, and the solution filtered. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give 20 g (50%) of [(5-methylimidazolyl)-4-methyl}-triphenylphosphonium chloride, mp 223-225°C.

Alternativt og fortrinnsvis fremstilles [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumklorid og bromid ved anvendelse av for-mamidinsulf insyre ved følgende fremgangsmåte'. Alternatively and preferably, [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride and bromide are prepared using formamidinsulfinic acid by the following method'.

Trifenyl-Ø-acetylvinyilfosfoniumklori<d> (3,65 g, 0,01 mol) og formamidinsulfinsyre (1,1 g, 0,01 mol) ble oppløst i 50 ml di-metylsulf oksyd . 1,8-bis-(dimetylamino)naftalin ("protonsvamp") Triphenyl-O-acetylvinylphosphonium chloride (3.65 g, 0.01 mol) and formamidine sulfinic acid (1.1 g, 0.01 mol) were dissolved in 50 ml of dimethylsulfoxide. 1,8-bis-(dimethylamino)naphthalene ("proton sponge")

(2,14 g, 0,01 mol) ble tilsatt og blandingen oppvarmet til 80°C. Etter avkjøling, avdampning av dimetylsulfoksyd, utfelling av (2.14 g, 0.01 mol) was added and the mixture heated to 80°C. After cooling, evaporation of dimethylsulfoxide, precipitation of

de uorganiske salter med kloroform, filtrering, inndampning til tørrhet og omkrystallisering av resten av kloroform-aceton fremkom et hovedsaklig kvantitativt utbytte av [(5-metylimidazolyl)-4- metyl]trifenylfosfoniumklorid. the inorganic salts with chloroform, filtration, evaporation to dryness and recrystallization of the residue from chloroform-acetone, a mainly quantitative yield of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride was obtained.

Trifenyl-B-acetylvinylfosfoniumbromid (20,6 g, 0,05 mol) og form-amidinsulf insyre (6,0 g, et lite overskudd over 0,05 mol) ble oppløst i 100 ml dimetylsulfoksyd. 1,5-diazabicyklo[5,4,0]undek-5- en (DBU) (7,6 g, 0,05 mol) ble tilsatt dråpevis under omrøring. Blandingen ble holdt ved 80°C i 20 min., og dimetylsulfoksydet ble avdampet. Resten ble opptatt i kloroform og uorganiske salter ble fjernet ved filtrering. Filtratet ble inndampet til tørrhet og resten ble omkrystallisert av kloroform-aceton og ga [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumbromid i et utbytte på 80%. Triphenyl-B-acetylvinylphosphonium bromide (20.6 g, 0.05 mol) and formamidinesulfonic acid (6.0 g, a slight excess over 0.05 mol) were dissolved in 100 mL of dimethyl sulfoxide. 1,5-diazabicyclo[5,4,0]undec-5-ene (DBU) (7.6 g, 0.05 mol) was added dropwise with stirring. The mixture was held at 80°C for 20 min., and the dimethyl sulfoxide was evaporated. The residue was taken up in chloroform and inorganic salts were removed by filtration. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide in 80% yield.

Til en oppløsning av 39,3 g (0,1 mol) [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumklorid i 200 ml metanol ble det satt 22 ml 25% natriummetoksyd i metanol, og reaksjonsblandingen ble oppvarmet under tilbakekjøling i 1 time. Etter avkjøling ble opp-løsningen fortynnet med 3 ganger sitt volum vann og filtrert for å fjerne trifenylfosfin. Filtratet ble ekstrahert med 4 porsjoner på 125 ml kloroform, og ekstraktene ble tørket (MgSO^) og inndampet til tørrhet til dannelse av 10,1 g (80%) 4-metoksy-metyl-5-metylimidazol som ble omdannet til det tilsvarende hydroklorid som beskrevet i eksempel 1, smeltepunkt 150°C. To a solution of 39.3 g (0.1 mol) [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride in 200 ml of methanol was added 22 ml of 25% sodium methoxide in methanol, and the reaction mixture was heated under reflux for 1 hour . After cooling, the solution was diluted with 3 times its volume of water and filtered to remove triphenylphosphine. The filtrate was extracted with 4 portions of 125 mL chloroform, and the extracts were dried (MgSO 4 ) and evaporated to dryness to give 10.1 g (80%) of 4-methoxy-methyl-5-methylimidazole which was converted to the corresponding hydrochloride as described in example 1, melting point 150°C.

Eksempel 5 Example 5

Trifenyl-B-acetylvinylfosfoniumbromid (4,11 g, 0,01 mol) ble i en porsjon satt til en omrørt suspensjon av 1,1 g (0,01 mol) formamidinsulfinsyre i 20 ml dimetylsulfoksyd inneholdende 0,25 g natriumhydrid. Blandingen ble omrørt ved omgivelsestemperatur i 1 time og derpå ved 80°C i ytterligere 1 time. Triphenyl-B-acetylvinylphosphonium bromide (4.11 g, 0.01 mol) was added in one portion to a stirred suspension of 1.1 g (0.01 mol) of formamidine sulfinic acid in 20 ml of dimethyl sulfoxide containing 0.25 g of sodium hydride. The mixture was stirred at ambient temperature for 1 hour and then at 80°C for an additional 1 hour.

En oppløsning av 0,99 g (0,01 mol) av natriumsaltet av cysteamin, fremstilt ved tilsetning av 2 ekvivalenter natriummetoksyd til cysteamindihydroklorid i 10 ml metanol ble tilsatt, og den fremkomne blanding ble oppvarmet til 70 - 80°C i 4 timer. Blandingen ble fortynnet med 2 ganger sitt volum vann og trifenylfosfinet ble fjernet ved filtrering. Filtratet ble ekstrahert med 100 ml toluen og med 2 porsjoner på 100 ml kloroform. Kloroformekstraktene ble forenet, tørket (MgSC>4) og inndampet til tørrhet til dannelse av 4-(2-aminoetyl)tiometyl-4-metylimidazol. Dihydrokloridsaltet har smeltepunkt på 189-192°C. A solution of 0.99 g (0.01 mol) of the sodium salt of cysteamine, prepared by adding 2 equivalents of sodium methoxide to cysteamine dihydrochloride in 10 ml of methanol was added and the resulting mixture was heated to 70-80°C for 4 hours. The mixture was diluted with 2 times its volume of water and the triphenylphosphine was removed by filtration. The filtrate was extracted with 100 ml of toluene and with 2 portions of 100 ml of chloroform. The chloroform extracts were combined, dried (MgSO4 ) and evaporated to dryness to give 4-(2-aminoethyl)thiomethyl-4-methylimidazole. The dihydrochloride salt has a melting point of 189-192°C.

Eksempel 6 Example 6

Anvendelse av et salt av et 2-substituert pseudotiourea som nedenfor anført: Use of a salt of a 2-substituted pseudothiourea as listed below:

2-benzylpseudotiourea 2-benzyl pseudothiourea

2-(4-klorbenzyl)pseudotiourea 2-(4-Chlorobenzyl)pseudothiourea

ved fremgangsmåten i eksempel 1 i stedet for 2-metylpseudotioureasulfat gir følgende trifenylfosfoniumbromidforbind-elser: [ (2-benzyltio-5-metylimidazolyl)-4-metyl]-trifenyl-fosfoniumbromid, smp. 193-194°C. by the method in example 1 instead of 2-methylpseudothioureasulfate gives the following triphenylphosphonium bromide compounds: [(2-benzylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide, m.p. 193-194°C.

[(2-(4-klorbenzyl)tio-5-metylimidazolyl)-4-metyl]-trifenylfosfoniumbromid, smp. 197-198°C. [(2-(4-chlorobenzyl)thio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide, m.p. 197-198°C.

Eksempel 7 Example 7

Til en oppløsning av 9,25 g (0,1 mol) B-klorallylalkohol i 100 To a solution of 9.25 g (0.1 mol) B-chloroallyl alcohol in 100

ml benzen settes en ekvivalent mengde av en vandig oppløsning av kromsvovelsyre (Jones reagens) og blandingen omrøres ved omgivelsestemperatur i 1 time. Etter filtrering adskilles lagene og den organiske fase vaskes med vann. Trifenylfosfin (26,2 g, 0,1 mol) settes til benzenoppløsningen og den oppvarmes under tilbakekjøling. Bunnfallet som dannes ved avkjøling oppsamles ved filtrering og tørkes og gir B-formylvinylfosfoniumklorid. ml of benzene, an equivalent amount of an aqueous solution of chromosulfuric acid (Jones reagent) is added and the mixture is stirred at ambient temperature for 1 hour. After filtration, the layers are separated and the organic phase is washed with water. Triphenylphosphine (26.2 g, 0.1 mol) is added to the benzene solution and it is heated under reflux. The precipitate formed on cooling is collected by filtration and dried to give B-formylvinylphosphonium chloride.

Når en ekvivalent mengde ji-formylvinylfosfoniumklorid får lov å reagere When an equivalent amount of ji-formylvinylphosphonium chloride is allowed to react

med formamidinsulfinsyre som beskrevet i fremgangsmåten i eksempel 4, fremstilles (imidazolyl-4-metyl)trifenylfosfoniumklorid. with formamidinesulfinic acid as described in the method in example 4, (imidazolyl-4-methyl)triphenylphosphonium chloride is prepared.

Reaksjon av (imidazolyl-4-metyl)trifenylfosfoniumklorid med cysteamin i nærvær av natriummetoksyd-eller natriumhydrid som ovenfor beskrevet gir 4(-2-aminoetyl)tiometylimidazol. Dihydrobromidsaltet av 4-(2-aminoetyl)-tiometylimidazol har et smeltepunkt på 178-179°C. Reaction of (imidazolyl-4-methyl)triphenylphosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described above gives 4(-2-aminoethyl)thiomethylimidazole. The dihydrobromide salt of 4-(2-aminoethyl)-thiomethylimidazole has a melting point of 178-179°C.

På lignende måte fortrenges trifenylfosfoniumgruppen i (imidazo-lyl-4-metyl)trifenylfosfoniumklorid ved reaksjon med andre nukleo-filer ved fremgangsmåten ifølge oppfinnelsen. In a similar way, the triphenylphosphonium group in (imidazolyl-4-methyl)triphenylphosphonium chloride is displaced by reaction with other nucleophiles in the method according to the invention.

Eksempel s Example p

Tri-n-butylfosfin (20,2 g, 0,1 mol) settes til en oppløsning av 10,4 g (0,1 mol) klorvinylmetylketon i 250 ml benzen, og blandingen oppvarmes under tilbakekjøling i 1 time. Blandingen avkjøles og det utfelte materialet oppsamles ved filtrering og tørkes og gir tri-n-butyl-B-acetylvinylfosfoniumklorid. Tri-n-butylphosphine (20.2 g, 0.1 mol) is added to a solution of 10.4 g (0.1 mol) of chlorovinyl methyl ketone in 250 ml of benzene, and the mixture is heated under reflux for 1 hour. The mixture is cooled and the precipitate is collected by filtration and dried to give tri-n-butyl-B-acetylvinylphosphonium chloride.

Trietyl-B-acetylvinylfosfoniumklorid fremstilles som ovenfor beskrevet ved anvendelse av trietylfosfin i stedet for tri-n-butylfosfin. Triethyl-B-acetylvinylphosphonium chloride is prepared as described above using triethylphosphine instead of tri-n-butylphosphine.

Reaksjon av en ekvivalent mengde tri-n-butyl-B-acetylvinylfosfoniumklorid eller trietyl-B-acetylvinylfosfoniumklorid med formamidinsulfinsyre som beskrevet ved fremgangsmåten i eksempel 4 gir henholdsvis [(5-metylimidazolyl)-4-metyl]tri-n-butyl-fosfoniumklorid og [(5-metylimidazolyl)-4-metyl]trietylfosfo-niumklorid. Reaction of an equivalent amount of tri-n-butyl-B-acetylvinylphosphonium chloride or triethyl-B-acetylvinylphosphonium chloride with formamidinesulfinic acid as described by the method in example 4 gives respectively [(5-methylimidazolyl)-4-methyl]tri-n-butyl-phosphonium chloride and [(5-methylimidazolyl)-4-methyl]triethylphosphonium chloride.

Reaksjon av [(5-metylimidazolyl)-4-metyl]tri-n-butylfosfoniumklorid Reaction of [(5-methylimidazolyl)-4-methyl]tri-n-butylphosphonium chloride

eller [(5-metylimidazolyl)-4-metyl]trietylfosfoniumklorid med cysteamin i nærvær av natriummetoksyd eller natriumhydrid som ovenfor beskrevet gir 4-(2-aminoetyl)tiometyl-5-metylimidazol. Dihydrokloridsaltet av 4-(2-aminoetyl)tiometyl-5-metylimidazol har smeltepunkt 189-192°C. or [(5-methylimidazolyl)-4-methyl]triethylphosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described above gives 4-(2-aminoethyl)thiomethyl-5-methylimidazole. The dihydrochloride salt of 4-(2-aminoethyl)thiomethyl-5-methylimidazole has a melting point of 189-192°C.

Eksempel 9Example 9

Natriumamid (0,39 g, 0,01 mol) ble oppløst i 40 ml flytende ammo-niakk og det ble tilsatt 4,11 g (0,01 mol) [(5-metylimidazolyl)-4-metyl]trifenylfosfoniumbromid. Suspensjonen ble omrørt ved Sodium amide (0.39 g, 0.01 mol) was dissolved in 40 ml of liquid ammonia and 4.11 g (0.01 mol) of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide was added. The suspension was stirred at

-4 0°C i 1 time og fikk så lov å oppvarme til romtemperatur, -4 0°C for 1 hour and then allowed to warm to room temperature,

etter hvert som ammoniakken avdampet. Trifenylfosfinet ble ekstrahert av resten med benzen og de tilbakeblivne faste stof-fer ble opptatt i vann og ekstrahert med klorform. Kloroformekstraktene ble tørket og inndampet til dannelse av 4-aminome-tyl-5-metylimidazol i et utbytte på 70%. Dette amin ble oppvarmet under tilbakekjøling med et molært ekvivalent cysteamin as the ammonia evaporated. The triphenylphosphine was extracted from the residue with benzene and the remaining solids were taken up in water and extracted with chloroform. The chloroform extracts were dried and evaporated to give 4-aminomethyl-5-methylimidazole in a yield of 70%. This amine was heated under reflux with a molar equivalent of cysteamine

i eddiksyre og behandlet med saltsyre til dannelse av 4-(2-aminoetyl)tiometyl-5-metylimidazoldihydroklorid. Smp. 189-192°C. Dihydroklorid'salter av 4-aminometyl-5-metylimidazol smelter ved 240-242°C (spaltning). in acetic acid and treated with hydrochloric acid to form 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloride. Temp. 189-192°C. Dihydrochloride salts of 4-aminomethyl-5-methylimidazole melt at 240-242°C (decomposition).

Eksempel 10 Example 10

[(5-metyl-2-metyltioimidazolyl)-4-metyl]trifenylfosfoniumbro-mid (4,83 gr 0,01 mol) ble omrørt i 20 ml piperidin ved romtemperatur i 30 min., deretter oppvarmet under tilbakekjøling 1 time, avkjølt og filtrert. Filtratet ble inndampet under redusert trykk og kromatografert på en søyle av silikagel under anvendelse av kloroform/metanol som eluant, hvorved fremkom 5-metyl-2--metyltio-4-piperidinometylimidazol. Behandling med saltsyre og oppvarmning under tilbakekjøling av det fremkomne dihydrokloridsalt med et molært ekvivalent cysteamin i eddiksyre ga 4-(2-aminoetyl)tiometyl-5-metyl-2-metyltioimidazoldihydroklo-rid. Smp. 165°C. [(5-methyl-2-methylthioimidazolyl)-4-methyl]triphenylphosphonium bromide (4.83 g 0.01 mol) was stirred in 20 ml of piperidine at room temperature for 30 min., then heated under reflux for 1 hour, cooled and filtered. The filtrate was evaporated under reduced pressure and chromatographed on a column of silica gel using chloroform/methanol as eluent, whereby 5-methyl-2-methylthio-4-piperidinomethylimidazole was obtained. Treatment with hydrochloric acid and heating under reflux of the resulting dihydrochloride salt with a molar equivalent of cysteamine in acetic acid gave 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride. Temp. 165°C.

Ved samme fremgangsmåte, men under anvendelse av pyrrolidin i stedet for piperidin fremstilles 5-metyl-2-metyltio-4-pyrro-lidinometylimidazol^By the same procedure, but using pyrrolidine instead of piperidine, 5-methyl-2-methylthio-4-pyrrolidinomethylimidazole is prepared^

Ved på lignende måté å anvende morfolin i stedet for piperidin fremstilles 5-metyl-2-metyltio-4-morfolinometylimidazol. By similarly using morpholine instead of piperidine, 5-methyl-2-methylthio-4-morpholinomethylimidazole is prepared.

Smp. 79°C (spaltning). Temp. 79°C (decomposition).

Omdannelse av disse pyrrolidin og morfolinforbindelser til di-hydrokloridsaltene og behandling med cysteamin i eddiksyre gir 4-(2-aminoetyl)tiometyl-5-metyl-2-metyltioimidazoldihydro-klorid. Conversion of these pyrrolidine and morpholine compounds to the dihydrochloride salts and treatment with cysteamine in acetic acid gives 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride.

Eksempel li Example li

Dimetylamin (0,5 g, 0,01 mol) ble oppløst i 35 ml tetrahydrofu-ran, omrørt og avkjølt i et isbad mens det dråpevis under omrøring ble tilsatt 5 ml (0,01 mol) 2M butyllitium i heksan. Etter omrø-ring av blandingen i 15 min.' i kulden ble det tilsatt 3,93 g (0,01 mol)[(5-metylimidazolyl)-4-metyl]trifenylfosfoniumklorid og oppløsningen fikk lov å oppvarmes til romtemperatur. Etter om-røring i 2 timer ved romtemperatur ble oppløsningsmidlene avdampet og resten behandlet med 50 ml vann. Filtrering ga difenyl-fosfin. Det vandige filtrat ble ekstrahert med kloroform, tør-ket og inndampet til dannelse av 4-(N,N-dimetylaminometyl)-5-metylimidazol. Smp. 92-94°C. Dette amin ble så oppvarmet under tilbakekjøling med et molært ekvivalent cysteamin i eddiksyre og behandlet med saltsyre til dannelse av 4-(2-aminoetyl)-tiometyl-5-metylimidazoldihydroklorid. Smp. 189-192°C. Dimethylamine (0.5 g, 0.01 mol) was dissolved in 35 ml of tetrahydrofuran, stirred and cooled in an ice bath while 5 ml (0.01 mol) of 2M butyllithium in hexane was added dropwise with stirring. After stirring the mixture for 15 min.' in the cold, 3.93 g (0.01 mol)[(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride was added and the solution was allowed to warm to room temperature. After stirring for 2 hours at room temperature, the solvents were evaporated and the residue treated with 50 ml of water. Filtration gave diphenylphosphine. The aqueous filtrate was extracted with chloroform, dried and evaporated to give 4-(N,N-dimethylaminomethyl)-5-methylimidazole. Temp. 92-94°C. This amine was then heated under reflux with a molar equivalent of cysteamine in acetic acid and treated with hydrochloric acid to form 4-(2-aminoethyl)-thiomethyl-5-methylimidazole dihydrochloride. Temp. 189-192°C.

Ved samme fremgangsmåte, men under anvendelse av metylamin i stedet for dimetylamin fremstilles 4-(N-metylaminometyl)-5-metyl-imidazol. På samme måte, men med anvendelse av butylamin og di-butylamin fremstilles 4-(N-butylaminometyl)-5-metylimidazol og 4-(N,N-dibutylaminometyl)-5-metylimidazol. Oppvarmning under tilbakekjøling av disse mellomprodukter med cysteamin på den ovenfor beskrevne fremgangsmåte og behandling med saltsyre gir 4-(2-aminoetyl)tiometyl-5-metylimidazoldihydroklorid. By the same procedure, but using methylamine instead of dimethylamine, 4-(N-methylaminomethyl)-5-methyl-imidazole is prepared. In the same way, but using butylamine and dibutylamine, 4-(N-butylaminomethyl)-5-methylimidazole and 4-(N,N-dibutylaminomethyl)-5-methylimidazole are prepared. Heating under cooling of these intermediates with cysteamine in the above-described method and treatment with hydrochloric acid gives 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloride.

Eksempel 12 Example 12

N-cyano-N'-metyl-N"-merkaptoetylguanidin (1,58 g, 0,01 mol) ble oppløst i 15 ml metanol og det ble tilsatt 2,3 ml natriummetoksyd i metanol. Etter omrøring ved romtemperatur i 5 min. ble det tilsatt en suspensjon av 3,93 g [(5-metylimidazolyl)-4-me- . tyl]-trifenylfosfoniumklorid i 10 ml metanol. Oppløsningen ble oppvarmet under tilbakekjøling. Et like så stort volum vann ble tilsatt og det meste av metanolen ble fjernet ved for-dampning. Filtrering og vask med vann ga trifenylfosfin. Fil-tratetble behandlet med trekull, filtrert og konsentrert. Filtreringen ga N-cyano-N'-metyl-N"-[2-(5-metyl-4-imidazolylmetyl-tio)etyl]guanidin. Smp. 141-142°c. N-cyano-N'-methyl-N"-mercaptoethylguanidine (1.58 g, 0.01 mol) was dissolved in 15 ml of methanol and 2.3 ml of sodium methoxide in methanol was added. After stirring at room temperature for 5 min. to a suspension of 3.93 g of [(5-methylimidazolyl)-4-methyl]-triphenylphosphonium chloride in 10 ml of methanol was added. The solution was heated under reflux. An equal volume of water was added and most of the methanol was removed by evaporation. Filtration and washing with water gave triphenylphosphine. The filtrate was treated with charcoal, filtered and concentrated. Filtration gave N-cyano-N'-methyl-N"-[2-(5-methyl-4- imidazolylmethyl-thio)ethyl]guanidine. Temp. 141-142°c.

Eksempel 13 Example 13

En blanding av 6,6 g (0,03 mol) 4-(2-aminoetyl)tiometyl-5-metyl-2-metyltioimidazol og 6,6 g 50:50 nikkel-aluminiumlegering i 50 ml maur syre ble oppvarmet under tilbakekjøling i 3 timer. Metal-lene ble fjernet ved filtrering og filtratet ble inndampet til tørrhet. Resten ble oppløst i etanol og den etanoliske oppløs-ning ble mettet med hydrogensulfid og deretter filtrert. Filtratet ble mettet med hydrogensulfid . Tilsetning av etylacetat bevirket utfelling av 4-(2-aminoetyl)tiometyl-5-metylimidazol som dihydrokloridsaltet. A mixture of 6.6 g (0.03 mol) 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole and 6.6 g of 50:50 nickel-aluminum alloy in 50 ml of formic acid was heated under reflux in 3 hours. The metals were removed by filtration and the filtrate was evaporated to dryness. The residue was dissolved in ethanol and the ethanolic solution was saturated with hydrogen sulphide and then filtered. The filtrate was saturated with hydrogen sulfide. Addition of ethyl acetate caused precipitation of 4-(2-aminoethyl)thiomethyl-5-methylimidazole as the dihydrochloride salt.

På lignende måte fjernes den 2-substituerte tiogruppe fra de andre imidazolforbindelser hvori R 3 er en substituert tiogruppe og som er fremstilt ovenfor. In a similar manner, the 2-substituted thio group is removed from the other imidazole compounds in which R 3 is a substituted thio group and which are prepared above.

7,75 g kaliumkarbonat ble satt til en oppløsning av 14,6 g 4-(2-aminoetyl)tiometyl-5-metylimidazoldihydroklorid i 120 ml vann. Oppløsningen ble holdt ved omgivelsestemperatur i 15 min. og det ble tilsatt 5,15 g metylisotiocyanat. Etter oppvarmning under tilbakekjøling i 1/2 time ble oppløsningen langsomt av-kjølt til 5°C. Produktet ble oppsamlet og omkrystallisert av vann og ga N-metyl-N[2-(5-metyl-4-imidazolylmetyltio)etyl]-tiourea, smeltepunkt 150 - 152°C. 7.75 g of potassium carbonate was added to a solution of 14.6 g of 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloride in 120 ml of water. The solution was kept at ambient temperature for 15 min. and 5.15 g of methyl isothiocyanate was added. After heating under reflux for 1/2 hour, the solution was slowly cooled to 5°C. The product was collected and recrystallized from water to give N-methyl-N[2-(5-methyl-4-imidazolylmethylthio)ethyl]-thiourea, mp 150-152°C.

Eksempel 14 Example 14

4-metoksymetyl-5-metyl-2-metyltioimidazol (13,46 g, 0,078 mol) 4-Methoxymethyl-5-methyl-2-methylthioimidazole (13.46 g, 0.078 mol)

og ca. 25 g Raney-nikkel ble satt til 400 ml etanol, og blandingen ble oppvarmet under tilbakekjøling i 3 timer. Blandingen ble filtrert og filterkaken ble vasket med 25 ml etanol. Filtratet og vaskevæskené ble forenet og luftformig hydrogensulfid ble ledet inn i oppløsningen i 10 min.. Blandingen ble filtrert og filtratet ble inndampet til tørrhet og ga 8,63 g (88%) 4-metoksymetyl-5-metylimidazol. and approx. 25 g of Raney nickel was added to 400 ml of ethanol and the mixture was heated under reflux for 3 hours. The mixture was filtered and the filter cake was washed with 25 ml of ethanol. The filtrate and washing liquid were combined and gaseous hydrogen sulfide was passed into the solution for 10 min. The mixture was filtered and the filtrate was evaporated to dryness to give 8.63 g (88%) of 4-methoxymethyl-5-methylimidazole.

4-metoksymetyl-5-metylimidazol ble omdannet til det tilsvarende hydroklorid som ovenfor beskrevet. 4-Methoxymethyl-5-methylimidazole was converted to the corresponding hydrochloride as described above.

4-metoksymetyl-5-metylimidazolhydroklorid (4,9 g, 0,03 mol) og 3,4 g (0,03 mol) cysteaminhydroklorid ble oppløst i en minimal mengde eddiksyre og blandingen ble oppvarmet under tilbakekjøling 4-Methoxymethyl-5-methylimidazole hydrochloride (4.9 g, 0.03 mol) and 3.4 g (0.03 mol) of cysteamine hydrochloride were dissolved in a minimal amount of acetic acid and the mixture was heated under reflux

i 18 timer. Etter avkjøling i et isbad ble blandingen filtrert og ga 5,8 g (80%) 4-(2-aminoetyl)tiometyl-5-metylimidazoldihydro-klorid. for 18 hours. After cooling in an ice bath, the mixture was filtered to give 5.8 g (80%) of 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloride.

På lignende måte blir de andre imidazoler som er fremstilt oven- In a similar manner, the other imidazoles prepared above are

for og hvori R 2 er en alkoksygruppe og R 3 er en substituert tiogruppe brakt til å reagere med Raney-nikkel etterfulgt av be- for and wherein R 2 is an alkoxy group and R 3 is a substituted thio group reacted with Raney nickel followed by be-

handling av det således dannede produkt med cysteamin i eddiksyre til dannelse av de tilsvarende 4-(2-aminoetyl)tiometylimidazoler. treatment of the product thus formed with cysteamine in acetic acid to form the corresponding 4-(2-aminoethyl)thiomethylimidazoles.

(a) En oppløsning av 17,0 g 4-(2-aminoetyl)-tiometyl-5-metylimi- (a) A solution of 17.0 g of 4-(2-aminoethyl)-thiomethyl-5-methylimi-

dazol og 11,2 g N-cyano-N',S-dimetylisotiourea i 500 ml dazole and 11.2 g of N-cyano-N',S-dimethylisothiourea in 500 ml

acetonitril ble oppvarmet under tilbakekjøling i 24 timer. Blan- acetonitrile was heated under reflux for 24 h. Blan-

dingen ble konsentrert og resten ble kromatografert på en søyle av silikagel med acetonitril som eluant. Det fremkomne produkt ble omkrystallisert av acetonitril-eter til dannelse av N-cyano-N<1->metyl-N"-[2-(5-metyl-4-imidazolylmetyltio)etyl]guanidin, the product was concentrated and the residue was chromatographed on a column of silica gel with acetonitrile as eluent. The resulting product was recrystallized from acetonitrile ether to form N-cyano-N<1->methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine,

smeltepunkt 141 - 142°C. melting point 141 - 142°C.

(b) En oppløsning av 23,4 g 4-(2-aminoetyl)tiometyl-5-metylimi- (b) A solution of 23.4 g of 4-(2-aminoethyl)thiomethyl-5-methylimi-

dazol i etanol ble langsomt satt til en oppløsning av 20,0 g dimetyl-N-cyanoimidoditiokarbonat i etanol under omrøring ved omgivelsestemperatur. Filtreringen ga N-cyano-N'-[2-(5-metyl-4-imidazolylmetyltio)etyl]-S-metylisotiourea, smeltepunkt 148 - 150°C. Filtratet ble konsentrert under et redusert trykk, dazole in ethanol was slowly added to a solution of 20.0 g of dimethyl-N-cyanoimidodithiocarbonate in ethanol with stirring at ambient temperature. The filtration gave N-cyano-N'-[2-(5-methyl-4-imidazolylmethylthio)ethyl]-S-methylisothiourea, melting point 148-150°C. The filtrate was concentrated under reduced pressure,

og blandingen ble triturert med kaldt vann og ga et fast materi- and the mixture was triturated with cold water to give a solid

ale, som ble oppsamlet ved filtrering og omkrystallisert 2 gan- ale, which was collected by filtration and recrystallized 2 times

ger av isopropanoleter, smeltepunkt 148 - 150°C. ger of isopropanol ether, melting point 148 - 150°C.

En oppløsning av 75 ml 33% metylamin i etanol ble satt til en A solution of 75 ml of 33% methylamine in ethanol was added to a

oppløsning av 10,1 g N-cyano-N<1->[2-(5-metyl-4-imidazolylmetyl-tio)etyl]-S-metylisotiourea i 30 ml etanol. Réaksjons- solution of 10.1 g of N-cyano-N<1->[2-(5-methyl-4-imidazolylmethyl-thio)ethyl]-S-methylisothiourea in 30 ml of ethanol. reaction

blandingen ble satt til side ved omgivelsestemperatur i 2 1/2 the mixture was set aside at ambient temperature for 2 1/2

time. Etter konsentrasjon under redusert trykk ble resten omkrystallisert 2 ganger av isopropanol-petroleumseter og ga N-cyano-N<1->metyl-N"-[2-(5-metyl-4-imidazolylmetyltio)etyl]guani- hour. After concentration under reduced pressure, the residue was recrystallized twice from isopropanol-petroleum ether to give N-cyano-N<1->methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guani-

din, smeltepunkt 141 - 143°C. din, melting point 141 - 143°C.

Eksempel 15 Example 15

Ved anvendelse av [(2-metyltio-5-metylimidazolyl)-4-metyl]-trifenylfosfoniumbromid i stedet for fosfoniumforbindelsen ved f remangsmåten i eksempel 12 fås N-cyano-N'-metyl-N'1-[2-(2-metyltio-5-metyl-4-imidazolylmetyltio)etyl]guanidin. 2-metyl-tiogruppen fjernes ved oppvarmning under tilbakekjøling av en blanding av forbindelsen og 50:50 nikkel-aluminiumlegering i maursyre og opparbeiding ved fremgangsmåten i eksempel 13 til dannelse av N-cyano-N1-metyl-N"-[ 2-(5-metyl-4-imidazolylmetyltio)etyl]-guanidin. Smp. 141-142°C. By using [(2-methylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide instead of the phosphonium compound in the procedure in example 12, N-cyano-N'-methyl-N'1-[2-(2- methylthio-5-methyl-4-imidazolylmethylthio)ethyl]guanidine. The 2-methyl-thio group is removed by heating under cooling a mixture of the compound and 50:50 nickel-aluminum alloy in formic acid and working up by the method in example 13 to form N-cyano-N1-methyl-N"-[ 2-(5 -methyl-4-imidazolylmethylthio)ethyl]-guanidine, mp 141-142°C.

Claims (2)

1. Fremgangsmåte ved fremstilling av en forbindelse med formelen hvor R 1 er hydrogen eller alkyl med 1-4 C-atomer, R 2er metoksy, etoksy, n-propoksy, n-butoksy, i-butoksy, t-butoksy, -SCH2CH2NH2 eller -NR<6>R<7> hvor R<6> og R<7> hver er hydrogen, alkyl-med-1-4 C-atomer eller sammen med nitrogenatomet hvortil de er 3bundet danner en piperidin, pyrrolidin eller morfolinring og R er hydrogen, alkyl med 1-4 C-atomer, trifluormetyl, eller -SR4, hvor R4 er alkyl med 1-4 C-atomer, benzyl eller klorbenzyl, karakterisert ved reaksjon av en forbindelse med formelen: hvor R og R har den ovennevnte betydning, R er alkyl med 1-4 C-atomer eller fenyl, og X er halogen med en forbindelse av formelen R<2->H, hvor R2 er som ovenfor definert i et organisk oppløs-ningsmiddel under basiske betingelser, hvoretter den erholdte forbindelse eventuelt omdannes til et syreaddisjonssalt.1. Procedure for the preparation of a compound with the formula where R 1 is hydrogen or alkyl with 1-4 C atoms, R 2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy, -SCH2CH2NH2 or -NR<6>R<7> where R<6> and R<7> are each hydrogen, alkyl-with-1-4 C atoms or together with the nitrogen atom to which they are 3-bonded form a piperidine, pyrrolidine or morpholine ring and R is hydrogen, alkyl with 1-4 C atoms, trifluoromethyl, or -SR4, where R4 is alkyl with 1-4 C atoms, benzyl or chlorobenzyl, characterized by reaction of a compound with the formula: where R and R have the above meaning, R is alkyl with 1-4 C atoms or phenyl, and X is halogen with a compound of the formula R<2->H, where R2 is as defined above in an organic solvent under basic conditions, after which the compound obtained is optionally converted into an acid addition salt. 2. Fremgangsmåte ifølge krav 1, karakterisert ved at reaksjonen utføres ved en temperatur på 65 C til 100°C i 20 min. til 3 timer.2. Method according to claim 1, characterized in that the reaction is carried out at a temperature of 65°C to 100°C for 20 min. to 3 hours.
NO771453A 1977-02-22 1977-04-26 PROCEDURE FOR PREPARING IMIDAZOLE COMPOUNDS NO152903C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/771,044 US4119781A (en) 1975-10-29 1977-02-22 Process for preparing 4-substituted imidazole compounds

Publications (3)

Publication Number Publication Date
NO771453L NO771453L (en) 1978-08-23
NO152903B true NO152903B (en) 1985-09-02
NO152903C NO152903C (en) 1985-12-11

Family

ID=25090518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO771453A NO152903C (en) 1977-02-22 1977-04-26 PROCEDURE FOR PREPARING IMIDAZOLE COMPOUNDS

Country Status (22)

Country Link
AR (1) AR217073A1 (en)
AT (1) AT355015B (en)
BE (1) BE853954R (en)
CA (1) CA1084052A (en)
CH (2) CH631167A5 (en)
DE (1) DE2718715A1 (en)
DK (1) DK168277A (en)
ES (1) ES458153A1 (en)
FI (1) FI73208C (en)
FR (1) FR2381031A2 (en)
GB (1) GB1582865A (en)
HU (1) HU174840B (en)
IE (1) IE45035B1 (en)
IL (1) IL51898A (en)
IN (1) IN148285B (en)
IT (1) IT1078449B (en)
LU (1) LU77200A1 (en)
MX (1) MX4663E (en)
NL (1) NL7704617A (en)
NO (1) NO152903C (en)
PT (1) PT66446B (en)
SE (2) SE442199B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57415A (en) * 1978-05-30 1984-08-31 Smith Kline French Lab Nitropyrrole compounds,process for preparing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MX4663E (en) 1982-07-21
PT66446B (en) 1978-09-22
SE452887B (en) 1987-12-21
AR217073A1 (en) 1980-02-29
ES458153A1 (en) 1978-04-01
CH631168A5 (en) 1982-07-30
NO152903C (en) 1985-12-11
NO771453L (en) 1978-08-23
DE2718715A1 (en) 1978-08-31
FR2381031A2 (en) 1978-09-15
ATA289577A (en) 1979-07-15
CA1084052A (en) 1980-08-19
IN148285B (en) 1981-01-03
LU77200A1 (en) 1977-08-17
SE8008935L (en) 1980-12-18
FI73208B (en) 1987-05-29
FI73208C (en) 1987-09-10
SE7704870L (en) 1978-08-23
HU174840B (en) 1980-03-28
AT355015B (en) 1980-02-11
BE853954R (en) 1977-10-26
DK168277A (en) 1978-08-23
IT1078449B (en) 1985-05-08
IE45035L (en) 1978-08-22
CH631167A5 (en) 1982-07-30
FI771291A (en) 1978-08-23
GB1582865A (en) 1981-01-14
IL51898A (en) 1980-07-31
SE442199B (en) 1985-12-09
NL7704617A (en) 1978-08-24
FR2381031B2 (en) 1982-09-17
IL51898A0 (en) 1977-06-30
PT66446A (en) 1977-05-01
IE45035B1 (en) 1982-06-02

Similar Documents

Publication Publication Date Title
US4013678A (en) Process for preparing heterocyclicalkylthioalkyl-n-cyanoguanidines
DK145907B (en) PROCEDURE FOR THE PREPARATION OF 2-ARYLAMINO-2-IMIDAZOLINE DERIVATIVES OR SALTS THEREOF
HU196377B (en) Process for production of 2-substituated-amin-5-acethilimidasoles
US2579478A (en) Heterocyclic compounds
US4119781A (en) Process for preparing 4-substituted imidazole compounds
NO152903B (en) PROCEDURE FOR PREPARING IMIDAZOLE COMPOUNDS
US4093621A (en) Process for preparing heterocyclicalkylthioalkyl-N-cyanoguanidines and thioureas
US4215217A (en) Process for preparing 4-substituted imidazole compounds
US7459552B2 (en) Method for producing cyclic diamine derivative or salt thereof
US4267337A (en) Imidazolemethylphosphonium salts
JPS5934709B2 (en) Method for producing chlorinated imidazole derivatives
SU615858A3 (en) Method of obtaining 2-aminothiazole acylated derivatives or salts thereof
JPS6296481A (en) Manufacture of n-sulfamyl-3- (2-guanidino-thiazole-4-yl-methylthio)-propioneamidine
US4151210A (en) Process for the production of phenylalkyl sulphones
DK146625B (en) 2-HALOGEN-4- (PROTECTED AMINO) QUINAZOLINE DERIVATIVES USED AS INTERMEDIATES IN THE PREPARATION OF 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -4-AMINO-6,7-DIMETHOXYQUINAZINE
EP0069445B1 (en) Process for making benzimidazoles
US4049669A (en) Process for preparing 5-(alkoxy- and aminoethyl thio)methylthiazole compounds
US3299081A (en) Chemical processes for preparing nu-substituted amidines
SE436571B (en) IMIDAZOLYLMETHYLTRIFENYL PHOSPHONIUM DERIVATIVES USED AS INTERMEDIATE FOR THE PREPARATION OF HISTAMINE H? 712 ANTAGONISTS
US4705861A (en) Aminophenylbenzothiazoles
US2535971A (en) 1-carbalkoxy-4-substituted piperazines
EP0744399B1 (en) Conversion of substituted 8-chloroquinolines to substituted 8-hydroxyquinolines
US5162534A (en) Process for the preparation of thiazoline derivatives
US3803163A (en) Process for the preparation of 1-(5-nitrothiazol-2-yl)-imidazolidinones
HU182782B (en) Process for producing alkylthio-benzimidazoles